Skip to main content

Terconazole

Generic: Terconazole

Verified·Apr 23, 2026
Manufacturer
Janssen
NDC
50090-6299
RxCUI
313227
Route
VAGINAL
ICD-10 indication
B37.3

Affordability Check

How much will you actually pay for Terconazole?

In 30 seconds, see every legitimate way to afford Terconazole — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Terconazole

What is this medication? Terconazole is an antifungal medication primarily prescribed to treat vaginal yeast infections, also known as vaginal candidiasis. This medication works by inhibiting the growth of the yeast or fungi that are causing the infection, which helps to relieve symptoms such as itching, burning, and unusual vaginal discharge. It is specifically designed to target the fungal organisms responsible for these issues and is effective in clearing the infection when used as directed by a healthcare provider.

The medication is typically available in the form of a vaginal cream or a suppository and is intended for local application. Patients are usually instructed to insert the medication into the vagina once daily, often at bedtime, for a specific number of days as determined by the strength of the prescription. While it often helps to reduce discomfort within a short period, it is important to complete the full course of treatment even if symptoms disappear early to ensure the infection is fully treated and does not recur.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Terconazole. Official source: DailyMed (NLM) · Label effective Jan 3, 2023

Indications and usage
INDICATIONS AND USAGE Terconazole vaginal cream 0.8% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.8% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.
Dosage and administration
DOSAGE AND ADMINISTRATION One full applicatorful (5 g) of terconazole vaginal cream 0.8% (40 mg terconazole) should be administered intravaginally once daily at bedtime for three consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of terconazole vaginal cream 0.8% is not affected by menstruation.
Contraindications
CONTRAINDICATIONS Patients known to be hypersensitive to terconazole or to any of the components of the cream.
Warnings
WARNINGS None.
Drug interactions
Drug Interactions: The therapeutic effect of this product is not affected by oral contraceptive usage.
Adverse reactions
ADVERSE REACTIONS During controlled clinical studies conducted in the United States, patients with vulvovaginal candidiasis were treated with terconazole vaginal cream 0.8% for 3 days. Based on comparative analyses with placebo and a standard agent, the adverse experiences considered most likely related to terconazole vaginal cream 0.8% were headache (21% vs 16% with placebo) and dysmenorrhea (6% vs 2% with placebo). Genital complaints in general, and burning and itching in particular, occurred less frequently in the terconazole vaginal cream 0.8% 3 day regimen (5% vs. 6%-9% with placebo). Other adverse experiences reported with terconazole vaginal cream 0.8% were abdominal pain (3.4% vs. 1% with placebo) and fever (1% vs. 0.3% with placebo). The therapy-related dropout rate was 2.0% for the terconazole vaginal cream 0.8%. The adverse drug experience most frequently causing discontinuation of therapy was vulvovaginal itching, 0.7% with the terconazole vaginal cream 0.8% group and 0.3% with the placebo group.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Terconazole appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

66%

3,657 of 5,509 plans

Most common tier

Tier 3

On 34% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)71
22%
Tier 2 (generic)91
28%
Tier 3 (preferred brand)112
34%
Tier 4 (non-preferred brand)55
17%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 329 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.